Brazil's GLP‑1 weight‑loss drugs drive health research, sales surge and informal market
Recent studies in Brazil and the United States suggest that GLP‑1 agonists such as semaglutide and tirzepatide may lower the risk of cancer progression. An analysis of 12,112 patients with obesity‑related tumors found a 38%‑50% reduction in metastasis rates for breast, lung, colorectal and liver cancers among GLP‑1 users. Researchers note that further trials are needed to confirm a direct drug effect.
Pharmacy chain Pague Menos reported a 153% increase in GLP‑1 sales in the first quarter of 2026, with the drugs accounting for 9.1% of its revenue and a projected market value of R$ 50 billion by 2030. Lower prices from generic entries have broadened access, especially among middle‑income consumers.
The rapid weight loss induced by GLP‑1 therapy is reshaping Brazil’s plastic‑surgery landscape. Surgeons at the 2026 Jornada Paulista highlighted rising demand for body‑contouring procedures—abdominoplasty, mastopexy and brachioplasty—to address skin laxity and excess tissue after treatment.
A Scanntech study estimates that more than half of all GLP‑1 doses in Brazil are obtained through informal channels, driven by a 239% rise in overall consumption in early 2026. The informal market is linked to a modest decline in sales of high‑calorie foods such as beer, snacks and chocolate. "We observe a surplus in insulin‑syringe sales that points to significant off‑label GLP‑1 use," said Priscila Ariani of Scanntech.
Experts caution that while the metabolic benefits are promising, the drugs remain approved only for obesity and type‑2 diabetes and should be used under medical supervision.